JP2015535289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535289A5 JP2015535289A5 JP2015540796A JP2015540796A JP2015535289A5 JP 2015535289 A5 JP2015535289 A5 JP 2015535289A5 JP 2015540796 A JP2015540796 A JP 2015540796A JP 2015540796 A JP2015540796 A JP 2015540796A JP 2015535289 A5 JP2015535289 A5 JP 2015535289A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- following formulation
- tablet
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PURKAOJPTOLRMP-UHFFFAOYSA-N CC(C)(C)c(cc(C(C)(C)C)c(O)c1)c1NC(C1=CNc2ccccc2C1=O)=O Chemical compound CC(C)(C)c(cc(C(C)(C)C)c(O)c1)c1NC(C1=CNc2ccccc2C1=O)=O PURKAOJPTOLRMP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721622P | 2012-11-02 | 2012-11-02 | |
| US61/721,622 | 2012-11-02 | ||
| US201261728328P | 2012-11-20 | 2012-11-20 | |
| US61/728,328 | 2012-11-20 | ||
| US201361770668P | 2013-02-28 | 2013-02-28 | |
| US61/770,668 | 2013-02-28 | ||
| US201361824005P | 2013-05-16 | 2013-05-16 | |
| US61/824,005 | 2013-05-16 | ||
| US201361840668P | 2013-06-28 | 2013-06-28 | |
| US61/840,668 | 2013-06-28 | ||
| PCT/US2013/067952 WO2014071122A1 (en) | 2012-11-02 | 2013-11-01 | Pharmaceutical compositions for the treatment of cftr mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038741A Division JP2018090626A (ja) | 2012-11-02 | 2018-03-05 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015535289A JP2015535289A (ja) | 2015-12-10 |
| JP2015535289A5 true JP2015535289A5 (enExample) | 2016-12-15 |
| JP6302923B2 JP6302923B2 (ja) | 2018-03-28 |
Family
ID=50628072
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540796A Active JP6302923B2 (ja) | 2012-11-02 | 2013-11-01 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2018038741A Withdrawn JP2018090626A (ja) | 2012-11-02 | 2018-03-05 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2019087813A Active JP7003085B2 (ja) | 2012-11-02 | 2019-05-07 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2021214209A Pending JP2022034069A (ja) | 2012-11-02 | 2021-12-28 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018038741A Withdrawn JP2018090626A (ja) | 2012-11-02 | 2018-03-05 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2019087813A Active JP7003085B2 (ja) | 2012-11-02 | 2019-05-07 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
| JP2021214209A Pending JP2022034069A (ja) | 2012-11-02 | 2021-12-28 | Ｃｆｔｒが媒介する疾患の処置のための医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20140163068A1 (enExample) |
| EP (3) | EP2914248B2 (enExample) |
| JP (4) | JP6302923B2 (enExample) |
| KR (1) | KR102396897B1 (enExample) |
| CN (2) | CN104869982A (enExample) |
| AR (1) | AR093340A1 (enExample) |
| AU (4) | AU2013337730B2 (enExample) |
| BR (1) | BR112015009913B1 (enExample) |
| CA (1) | CA2890106C (enExample) |
| CL (1) | CL2015001148A1 (enExample) |
| CY (1) | CY1121070T1 (enExample) |
| DK (2) | DK3470063T3 (enExample) |
| ES (2) | ES2694290T5 (enExample) |
| FI (2) | FI2914248T4 (enExample) |
| HR (2) | HRP20250100T1 (enExample) |
| HU (2) | HUE039864T2 (enExample) |
| IL (2) | IL283276B2 (enExample) |
| LT (2) | LT2914248T (enExample) |
| MX (2) | MX368353B (enExample) |
| NZ (2) | NZ708474A (enExample) |
| PL (2) | PL2914248T5 (enExample) |
| PT (2) | PT2914248T (enExample) |
| RS (2) | RS66596B1 (enExample) |
| SG (3) | SG10201703452PA (enExample) |
| SI (2) | SI3470063T1 (enExample) |
| SM (2) | SMT202500078T1 (enExample) |
| TR (1) | TR201815218T4 (enExample) |
| TW (2) | TW201422253A (enExample) |
| UA (2) | UA117464C2 (enExample) |
| WO (1) | WO2014071122A1 (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| MX2008002019A (es) | 2005-08-11 | 2008-04-16 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de fibrosis quistica. |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| NZ596889A (en) | 2006-04-07 | 2013-06-28 | Vertex Pharma | Use of amide indole derivatives as modulators of ATP-binding cassette transporters |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| CN102863432B (zh) | 2007-05-09 | 2016-09-07 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
| HUE028426T2 (en) | 2007-08-24 | 2016-12-28 | Vertex Pharma | Isothiazolopyridinones for (inter alia) treating cystic fibrosis |
| ES2556080T3 (es) | 2007-11-16 | 2016-01-12 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
| KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| WO2009076142A2 (en) | 2007-12-07 | 2009-06-18 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| CN106432213A (zh) | 2008-02-28 | 2017-02-22 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| MX384179B (es) | 2009-03-20 | 2025-03-14 | Vertex Pharma | Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística. |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| BR112012026255A2 (pt) | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| RU2745977C2 (ru) | 2010-04-22 | 2021-04-05 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| KR101985044B1 (ko) | 2011-11-08 | 2019-05-31 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송체의 조절제 |
| ES2793148T3 (es) | 2012-01-06 | 2020-11-13 | Lundbeck La Jolla Research Center Inc | Compuestos de carbamato y métodos para fabricarlos y usarlos |
| DK2806859T3 (da) | 2012-01-25 | 2019-08-05 | Vertex Pharma | Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| SMT202500078T1 (it) * | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| US9303918B2 (en) * | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
| WO2014176553A1 (en) * | 2013-04-26 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| DK3068392T5 (da) * | 2013-11-12 | 2021-09-20 | Vertex Pharma | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme |
| SG10201913575VA (en) | 2014-04-15 | 2020-02-27 | Vertex Pharma | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| EP3798214B1 (en) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3204358B1 (en) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2016081556A1 (en) | 2014-11-18 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
| CA2984480A1 (en) | 2015-05-11 | 2016-11-17 | Abide Therapeutics, Inc. | Methods of treating inflammation or neuropathic pain |
| MA42954A (fr) | 2015-09-25 | 2018-08-01 | Vertex Pharmaceuticals Europe Ltd | Potentialisateurs cftr deutérés |
| WO2017151725A1 (en) * | 2016-03-03 | 2017-09-08 | Nivalis Therapeutics, Inc. | Formulations of an s-nitrosoglutathione reductase inhibitor |
| EP3436446B1 (en) | 2016-03-31 | 2023-06-07 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| HUP1600270A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei |
| HUP1600271A2 (hu) * | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| SG10201913595YA (en) | 2016-09-30 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EP3541807B1 (en) | 2016-11-16 | 2021-09-29 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| AU2017361254B2 (en) | 2016-11-16 | 2021-09-23 | H. Lundbeck A/S. | Pharmaceutical formulations |
| MA49235B1 (fr) | 2016-12-09 | 2021-02-26 | Vertex Pharma | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| EP3634402B1 (en) | 2017-06-08 | 2026-01-21 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| IL273831B2 (en) | 2017-10-19 | 2024-10-01 | Vertex Pharma | Crystalline forms and compositions of cftr modulators |
| SG11202004264VA (en) | 2017-12-01 | 2020-06-29 | Vertex Pharma | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| CN111757874B (zh) | 2017-12-08 | 2024-03-08 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3752510B1 (en) | 2018-02-15 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| WO2019195739A1 (en) | 2018-04-05 | 2019-10-10 | Alexander Russell Abela | Modulators of cystic fibrosis transmembrane conductance regulator |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| AU2019381750B2 (en) | 2018-11-14 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| MX2022001827A (es) | 2019-08-14 | 2022-06-09 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica. |
| US11904006B2 (en) | 2019-12-11 | 2024-02-20 | University Of Iowa Research Foundation | Poly(diaminosulfide) particle-based vaccine |
| CN115427403A (zh) | 2020-04-21 | 2022-12-02 | H.隆德贝克有限公司 | 单酰基甘油脂肪酶抑制剂的合成 |
| WO2022194399A1 (en) | 2020-07-13 | 2022-09-22 | Idorsia Pharmaceuticals Ltd | Macrocycles as cftr modulators |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| CA3188787A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| CN116670143A (zh) | 2020-10-07 | 2023-08-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| WO2022076626A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CR20230198A (es) | 2020-10-07 | 2023-07-03 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| TW202233635A (zh) | 2020-10-07 | 2022-09-01 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| US20240100183A1 (en) * | 2020-12-11 | 2024-03-28 | University Of Iowa Research Foundation | Compositions comprising molecules for cystic fibrosis treatment |
| CA3211232A1 (en) * | 2021-03-09 | 2022-09-15 | Hemant Bhagwat NARKHEDE | Oral film of cftr modulator(s) |
| JP2025506382A (ja) | 2022-02-03 | 2025-03-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症の治療方法 |
| AU2023218262A1 (en) | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20250008540A (ko) | 2022-04-06 | 2025-01-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
| CA3253026A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | TREATMENT METHODS FOR CYSTIC FIBROSIS |
| JP2025529476A (ja) | 2022-09-15 | 2025-09-04 | イドルシア・ファーマシューティカルズ・リミテッド | （３Ｓ，７Ｓ，１０Ｒ，１３Ｒ）－１３－ベンジル－２０－フルオロ－７－イソブチル－Ｎ－（２－（３－メトキシ－１，２，４－オキサジアゾール－５－イル）エチル）－６，９－ジメチル－１，５，８，１１－テトラオキソ－１０－（２，２，２－トリフルオロエチル）－１，２，３，４，５，６，７，８，９，１０，１１，１２，１３，１４－テトラデカヒドロ－［１］オキサ［４，７，１０，１４］テトラアザシクロヘプタデシノ［１６，１７－ｆ］キノリン－３－カルボキサミドの結晶形 |
| WO2024056791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators |
| CN119894906A (zh) | 2022-09-15 | 2025-04-25 | 爱杜西亚药品有限公司 | 大环cftr调节剂 |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| JP4977319B2 (ja) | 2002-09-30 | 2012-07-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 嚢胞性線維症膜コンダクタンス制御因子蛋白質阻害薬およびその使用方法 |
| US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| EP3345895B1 (en) | 2003-04-11 | 2019-12-04 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease |
| US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| EP1646615B1 (en) | 2003-06-06 | 2009-08-26 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| CA2465565A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| AU2004279855A1 (en) | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
| EP1682127B1 (en) | 2003-11-14 | 2009-07-29 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
| AU2005228685B2 (en) | 2004-03-30 | 2010-08-19 | The Regents Of The University Of California | Hydrazide-containing CFTR inhibitor compounds and uses thereof |
| AU2005251745A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| MX341797B (es) | 2004-06-24 | 2016-09-02 | Vertex Pharmaceuticals Incorporated * | Moduladores de transportadores con casete de union con atp. |
| WO2006044456A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| EP1865949B1 (en) | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| CA2603402C (en) | 2005-04-08 | 2017-10-31 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| JP5426878B2 (ja) | 2005-05-24 | 2014-02-26 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ−結合カセットトランスポーターのモジュレーター |
| CN101312722A (zh) | 2005-10-06 | 2008-11-26 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| ES2778846T3 (es) | 2005-11-08 | 2020-08-12 | Vertex Pharma | Moduladores heterocíclicos de transportadores de casete de unión a ATP |
| US8318935B2 (en) | 2007-05-07 | 2012-11-27 | Novartis Ag | Organic compounds 75074 |
| RU2010114732A (ru) * | 2007-09-14 | 2011-10-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида |
| KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[ｄ][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
| EP2231280B1 (en) | 2007-12-10 | 2016-08-10 | Novartis AG | Amiloride-like Pyrazine-carboxamides as ENaC blockers |
| BRPI0915018A2 (pt) | 2008-06-10 | 2015-10-27 | Novartis Ag | compostos orgânicos |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| LT3345625T (lt) | 2008-08-13 | 2021-02-10 | Vertex Pharmaceuticals Incorporated | Farmacinė kompozicija ir jos vartojimas |
| AU2009296271A1 (en) * | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN102803234A (zh) * | 2009-06-02 | 2012-11-28 | 霓坎制药有限责任公司 | 用于治疗疾病的人甲酰基肽受体的拮抗作用 |
| JP2011034380A (ja) * | 2009-08-03 | 2011-02-17 | Nitto Denko Corp | タッチパネルおよびタッチパネル付表示装置 |
| WO2011028740A1 (en) | 2009-09-03 | 2011-03-10 | Glaxo Group Limited | ENaC BLOCKERS |
| WO2011079087A1 (en) | 2009-12-23 | 2011-06-30 | Glaxo Group Limited | Enac blockers |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| BR112012026255A2 (pt) * | 2010-04-07 | 2017-03-14 | Vertex Pharma | composições farmacêuticas de ácido 3-(6-(1-(2-,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e administração das mesmas |
| AU2011242452A1 (en) * | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| US10105356B2 (en) * | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| DK2806859T3 (da) * | 2012-01-25 | 2019-08-05 | Vertex Pharma | Formuleringer af 3-(6-(1-(2.2-difluorbenzo[d][1,3]dioxol-5-yl) cyclopropancarboxamido)-3-methylpyridin-2-yl)benzoesyre |
| SMT202500078T1 (it) * | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| DK3068392T5 (da) * | 2013-11-12 | 2021-09-20 | Vertex Pharma | Fremgangsmåde til fremstilling af farmaceutiske sammensætninger til behandlingen af cftr-medierede sygdomme |
-
2013
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/it unknown
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/fi active
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/hu unknown
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/ja active Active
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/pl unknown
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/lt unknown
- 2013-11-01 MX MX2015005559A patent/MX368353B/es active IP Right Grant
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-01 TW TW102139864A patent/TW201422253A/zh unknown
- 2013-11-01 ES ES13792149T patent/ES2694290T5/es active Active
- 2013-11-01 ES ES18192504T patent/ES3009747T3/es active Active
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/zh active Pending
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 TW TW107117580A patent/TWI736768B/zh active
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/hr unknown
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/zh active Pending
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/tr unknown
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/hu unknown
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 PT PT13792149T patent/PT2914248T/pt unknown
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/ko active Active
- 2013-11-01 SI SI201332096T patent/SI3470063T1/sl unknown
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 UA UAA201505319A patent/UA117464C2/uk unknown
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en not_active Ceased
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/pl unknown
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/hr unknown
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/it unknown
- 2013-11-01 UA UAA201803746A patent/UA123631C2/uk unknown
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/da active
- 2013-11-01 SI SI201331163T patent/SI2914248T2/sl unknown
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/da active
- 2013-11-01 PT PT181925041T patent/PT3470063T/pt unknown
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/pt active IP Right Grant
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/fi active
- 2013-11-01 RS RS20250226A patent/RS66596B1/sr unknown
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 RS RS20181318A patent/RS57831B2/sr unknown
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 EP EP24223819.4A patent/EP4556008A3/en active Pending
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/lt unknown
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-04 AR ARP130104018A patent/AR093340A1/es not_active Application Discontinuation
-
2015
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/es unknown
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/es unknown
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
-
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
-
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/ja not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/el unknown
-
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/ja active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
-
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
-
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/ja active Pending
-
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
-
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535289A5 (enExample) | ||
| JP3563036B2 (ja) | セレコキシブ組成物 | |
| CN1633281A (zh) | 口内崩解的伐地考昔组合物 | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| CN104661649A (zh) | 包含替格瑞洛的固态口服医药制剂 | |
| JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| TWI418370B (zh) | 溶出安定性製劑 | |
| US20100152173A1 (en) | Tablet Having Improved Stability With At Least Two Actives | |
| JP6117591B2 (ja) | モサプリドと制酸剤とを含有する医薬組成物 | |
| AU2011276450A1 (en) | Pharmaceutical compositions containing vanoxerine | |
| JP2017520619A (ja) | セリチニブ製剤 | |
| WO2019124358A1 (ja) | 粒子径制御によるプレガバリンの化学的安定性の改善方法 | |
| KR20110063684A (ko) | 알리스키렌을 포함하는 생약 제형 및 용융 압출 과립화에 의한 그의 제조 방법 | |
| JP5873394B2 (ja) | タンニン酸ベルベリン粒子及びその製造方法、錠剤 | |
| CN1303284A (zh) | 8－氯－6,11－二氢－11－(4－亚哌啶基)－5H－苯并[5,6]环庚三烯并[1,2－b]吡啶口服组合物 | |
| WO2024086712A2 (en) | Solid pharmaceutical tablet | |
| JP7627568B2 (ja) | オセルタミビルを含む錠剤及びその製造方法 | |
| CN104994842B (zh) | 高剂量柠檬酸钾蜡基质缓释片剂 | |
| JP5680607B2 (ja) | 安定固形製剤及びその製造法 | |
| JP7109255B2 (ja) | 粉砕物の製造方法及び錠剤の製造方法 | |
| CN103877064B (zh) | 一种非诺贝特胶囊剂及其制备工艺 | |
| JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
| CA3143829C (en) | Pretomanid compositions | |
| JP7115825B2 (ja) | エゼチミブ含有経口製剤及びその製造方法 | |
| JP6558530B2 (ja) | アリピプラゾール医薬品製剤 |